Elicio Therapeutics (ELTX) Share-based Compensation (2020 - 2026)
Elicio Therapeutics (ELTX) reported Share-based Compensation of $868000.0 for Q1 2026, up 67.89% on a YoY basis from $517000.0 in Q1 2025, and up 12.44% quarter-over-quarter from $772000.0 in Q4 2025.
Elicio Therapeutics (ELTX) Share-based Compensation (2020 - 2026) Analysis & Trends
Elicio Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $868000.0 in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 67.89% year-over-year to $868000.0; the trailing twelve-month figure through Mar 2026 stood at $3.0 million (up 85.29% YoY), and the FY2025 full-year result was $2.7 million, up 85.74% from the prior year.
- Share-based Compensation for Q1 2026 stood at $868000.0, up from $772000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $868000.0 in Q1 2026, with the low at $31000.0 in Q1 2022.
- Historically, Share-based Compensation has averaged $398529.4 across 5 years, with a median of $337000.0 in 2023.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 99.39% — and 2023, when it soared 622.58%.
- Elicio Therapeutics' Share-based Compensation stood at $199000.0 in 2022, then jumped by 69.35% to $337000.0 in 2023, then surged by 37.69% to $464000.0 in 2024, then jumped by 66.38% to $772000.0 in 2025, then climbed by 12.44% to $868000.0 in 2026.
- The last three Share-based Compensation figures came in at $868000.0 (Q1 2026), $772000.0 (Q4 2025), and $698000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Elicio Therapeutics | 70.12 Mn | 55.17 Mn | - | 868,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 868,000.00 |
| Mar 31, 2026 | 868,000.00 |
| Dec 31, 2025 | 772,000.00 |
| Dec 31, 2025 | 772,000.00 |
| Sep 30, 2025 | 698,000.00 |
| Sep 30, 2025 | 698,000.00 |
| Jun 30, 2025 | 710,000.00 |
| Jun 30, 2025 | 710,000.00 |
| Mar 31, 2025 | 517,000.00 |
| Mar 31, 2025 | 517,000.00 |
| Dec 31, 2024 | 464,000.00 |
| Dec 31, 2024 | 464,000.00 |
| Sep 30, 2024 | 314,000.00 |
| Sep 30, 2024 | 314,000.00 |
| Jun 30, 2024 | 350,000.00 |
| Jun 30, 2024 | 350,000.00 |
| Mar 31, 2024 | 324,000.00 |
| Mar 31, 2024 | 324,000.00 |
| Dec 31, 2023 | 337,000.00 |
| Dec 31, 2023 | 337,000.00 |